Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

In a study by the Northwestern Medicine Canning Thoracic Institute in Chicago, the RNA in the SARS-CoV-2 virus was found to "trigger the development of a unique type of immune cell with anti-cancer ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with ...

The United States must address the growing public health crisis over high traffic deaths that remain significantly above ...

We consulted dietitians and reviewed the latest research to identify the healthiest foods you should consider incorporating ...

Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...

A Vitamin B supplement has been recalled due to being incorrectly formulated with niacin rather than niacinamide.